BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

NCT02706691 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Study stopped due to poor enrollment.

Conditions

FGFR Gene Amplification
FGFR1 Gene Amplification
FGFR2 Gene Amplification
FGFR2 Gene Mutation
FGFR3 Gene Mutation
Head and Neck Squamous Cell Carcinoma
Human Papillomavirus Infection
Recurrent Head and Neck Carcinoma
Recurrent Nasopharynx Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG: BGJ398

Sponsor

University of Chicago

Collaborators

[object Object]